|
Name |
Galiellalactone
|
Molecular Formula | C11H14O3 | |
IUPAC Name* |
(4R,7R,9S,11S)-11-hydroxy-9-methyl-3-oxatricyclo[5.3.1.04,11]undec-1(10)-en-2-one
|
|
SMILES |
C[C@H]1C[C@H]2CC[C@@H]3[C@]2(C(=C1)C(=O)O3)O
|
|
InChI |
InChI=1S/C11H14O3/c1-6-4-7-2-3-9-11(7,13)8(5-6)10(12)14-9/h5-7,9,13H,2-4H2,1H3/t6-,7+,9+,11-/m0/s1
|
|
InChIKey |
SOIISBQQYAGDKM-QJSROADHSA-N
|
|
Synonyms |
Galiellalactone; 133613-71-5; (-)-Galiellalactone; CHEMBL3823609; SCHEMBL17081865; NSC771565; ZINC96032826; AKOS006309836; NSC-771565; HY-125170; CS-0089754; (4S,5aR,7aR,7bS)-5,5a,6,7,7a,7b-Hexahydro-7b-hydroxy-4-methylindeno[1,7-bc]furan-2(4H)-one
|
|
CAS | NA | |
PubChem CID | 11310070 | |
ChEMBL ID | CHEMBL3823609 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 194.23 | ALogp: | 0.9 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 3 |
Heavy Atoms: | 14 | QED Weighted: | 0.594 |
Caco-2 Permeability: | -4.54 | MDCK Permeability: | 0.00004730 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.14 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.149 |
Blood-Brain-Barrier Penetration (BBB): | 0.963 | Plasma Protein Binding (PPB): | 59.80% |
Volume Distribution (VD): | 1.291 | Fu: | 45.44% |
CYP1A2-inhibitor: | 0.348 | CYP1A2-substrate: | 0.12 |
CYP2C19-inhibitor: | 0.087 | CYP2C19-substrate: | 0.666 |
CYP2C9-inhibitor: | 0.018 | CYP2C9-substrate: | 0.097 |
CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.424 |
CYP3A4-inhibitor: | 0.029 | CYP3A4-substrate: | 0.156 |
Clearance (CL): | 6.229 | Half-life (T1/2): | 0.19 |
hERG Blockers: | 0.034 | Human Hepatotoxicity (H-HT): | 0.965 |
Drug-inuced Liver Injury (DILI): | 0.345 | AMES Toxicity: | 0.534 |
Rat Oral Acute Toxicity: | 0.755 | Maximum Recommended Daily Dose: | 0.568 |
Skin Sensitization: | 0.262 | Carcinogencity: | 0.067 |
Eye Corrosion: | 0.074 | Eye Irritation: | 0.211 |
Respiratory Toxicity: | 0.936 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003700 | 0.444 | D0A2AJ | 0.236 | ||||
ENC005798 | 0.444 | D0G6AB | 0.232 | ||||
ENC003701 | 0.439 | D0K7LU | 0.222 | ||||
ENC003480 | 0.345 | D06AEO | 0.222 | ||||
ENC005043 | 0.305 | D0U3GL | 0.220 | ||||
ENC002040 | 0.293 | D0I2SD | 0.216 | ||||
ENC002355 | 0.282 | D04GJN | 0.216 | ||||
ENC004785 | 0.282 | D04CSZ | 0.214 | ||||
ENC004784 | 0.274 | D04JHN | 0.207 | ||||
ENC003670 | 0.268 | D0Q6NZ | 0.207 |